MetLife Investment Management Increases Investments in Viridian Therapeutics by 44.7% During Q4 FY2021

MetLife Investment Management LLC has been increasing its investments in Viridian Therapeutics, Inc. The institutional investor raises its shares in Viridian Therapeutics by 44.7% during the fourth quarter of the fiscal year 2021. The report was released on their most recent 13F filing with the Securities and Exchange Commission. At present, MetLife Investment Management LLC owns more than 19,000 shares in Viridian Therapeutics, which is worth $580,000.

Viridian Therapeutics is a clinical-stage biopharmaceutical company that specializes in developing proprietary RNA-targeted therapeutics for patients with certain cancers including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma. The company’s product candidates like Cobomarsen are designed for treating patients with pathological fibrosis.

The current stock value of VRDN as of last Friday is $25.41 after trading up by $0.49 with over three hundred thousand shares exchanged compared to an average volume of six hundred twenty-six thousand eight hundred fifty-one shares traded daily. With excellent liquidity ratios being reported in quick and current ratios at 12.93 each and a debt-to-equity ratio of only .02, it is evident that Viridian Therapeutics’s financial stability remains solid amidst volatile markets conditions.

As per the corporate disclosures made via filings with SEC databases governed by regulations set forth under US law predicate on provisions prescribed within Section-16A Act-1934 legislation concerning registrant companies thereof; added investment allocations sourcing from renowned institutional investors such as MetLife Investment Management LLC have substantiated market confidence around Viridian Therapeutic’s ability to deliver reliable return yields to clients’ portfolios regardless of economic down cycles or global market fluctuations.

In conclusion, such investments generate high yield returns while mitigating potential losses for both individual and institutional investors invested in similar sectors seeking higher risk-reward payoffs enabling one to attain desired wealth accumulation targets faster. Hence Viridian Therapeutics, Inc. remains a promising market entry within the biopharmaceutical sector safeguarding investor interests and providing excellent returns on investments.

Viridian Therapeutics Sees Increased Investor Interest Despite Earnings Miss

Viridian Therapeutics Inc., a clinical stage biopharmaceutical company specializing in RNA-targeted therapeutics, has seen increased interest from hedge funds and other investors recently. Metropolitan Life Insurance Co NY raised its position in Viridian by 47% during the fourth quarter, while Zurcher Kantonalbank Zurich Cantonalbank, Silverarc Capital Management LLC, Legal & General Group Plc, and Royal Bank of Canada all acquired new positions in the company. Despite this attention from investors, insiders have also been selling shares. Barrett Katz sold 4,147 shares at an average price of $37.01 and Jonathan Violin sold 50,000 shares at an average price of $36.80.

Viridian’s product candidates include Cobomarsen for treating certain cancers like cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma; Remlarsen for treating patients with pathological fibrosis; and MRG-229 for the treatment of fibrosis-related disorders. However, the company missed analysts’ consensus estimates of earnings per share (EPS) during its most recent quarterly earnings report on March 8th.

Despite this setback, Viridian Therapeutics has received strong ratings from various analysts. Cowen and SVB Leerink both rated the stock as “outperform”, while Ladenburg Thalmann rated it as a “buy”. Needham & Company also initiated coverage on Viridian with a buy rating and a target price of $45.00 per share.

Overall, Viridian Therapeutics is experiencing varied interest from investors and analysts alike. Though some have chosen to sell shares recently, others see potential in their RNA-targeted therapeutics program and view VRDN as a buy opportunity with potential for growth in the long-term.